Michael Kauffman

13.6k citations

190 papers · 5.6k indexed · 2 hit papers · h-index 41

Impact in

Hematology top 0.5%
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
Oncology top 1%
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis

Papers in

Hematology 50
- Multiple Myeloma Research and Treatments 33
- Acute Myeloid Leukemia Research 17
Molecular Biology 153
- Nuclear Structure and Function 111
- Protein Degradation and Inhibitors 23
- RNA Research and Splicing 20
- Ubiquitin and proteasome pathways 15

Co-authors: Julian Adams Sharon Shacham Thomas J. Kelly Yosef Landesman Dilara McCauley Asfar S. Azmi William Senapedis Amro Aboukameel
Journals: Blood (48 papers)Journal of Clinical Oncology (36 papers)Cancer Research (27 papers)Oncotarget (11 papers)Annals of Oncology (7 papers)
Partner nations: United States Canada Denmark

In The Last Decade

Michael Kauffman

186 papers receiving 5.5k citations

Hit Papers

align trajectories log scale

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma 2004 · 569 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2004 British Journal of Haematology
2004 Cancer Investigation

Peers

Countries citing papers authored by Michael Kauffman

Since Specialization

Citations

This map shows the geographic impact of Michael Kauffman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kauffman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kauffman more than expected).

Fields of papers citing papers by Michael Kauffman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Kauffman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kauffman. The network helps show where Michael Kauffman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael Kauffman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Kauffman Line = papers co-authored together Michael Kauffman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma Clinical Cancer Research ·Andrew B. Lassman, Patrick Y. Wen, Martin J. van den Bent, Scott R. Plotkin, Annemiek Walenkamp, Adam L. Green, Kai Li, Christopher J. Walker, Hua Chang, Sharon Tamir, 陈秀莲, Yao Shen, Mariano J. Alvarez, Andrea Califano, Yosef Landesman, Michael Kauffman, 吉留, Morten Mau‐Sørensen	2021	40
2	Health-Related Quality of Life and Pain with Selinexor in Patients with Advanced Dedifferentiated Liposarcoma Future Oncology ·Mrinal M. Gounder, Albiruni R. Abdul Razak, Adrienne M. Gilligan, Hoyee Leong, Xiwen Ma, Neeta Somaiah, Sant P. Chawla, Javier Martín‐Broto, Giovanni Grignani, Scott M. Schuetze, Bruno Vincenzi, Andrew J. Wagner, Bartosz Chmielowski, Robin L. Jones, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Richard F. Riedel, Steven Attia	2021	13
3	Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome Blood ·E.E. ZIMINA, Bhavana Bhatnagar, Sanjay Mohan, William Senapedis, Erkan Baloglu, Hongwei Wang, Jatin J. Shah, Sharon Shacham, Michael Kauffman	2019	4
4	Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib Journal of Cancer ·Wenwen Chien, Makoto Sudo, Ling‐Wen Ding, Qiao‐Yang Sun, Thǭ. Līangphibūn, Kian Leong Lee, Norimichi Hattori, Manoj Garg, Liang Xu, Yun Zheng, Sigal Gery, Javier Cassel, Henry Yang, Erkan Baloglu, Sharon Shacham, Michael Kauffman, Seiichi Mori, H. Phillip Koeffler	2018	28
5	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma Blood ·John Kuruvilla, Michael R. Savona, Rachid Baz, Morten Mau‐Sørensen, Nashat Gabrail, Ramiro Garzon, Richard M. Stone, Michael Wang, Lynn Savoie, Peter Martin, Ian W. Flinn, Meagan A. Jacoby, Thaddeus J. Unger, Jean-Richard Saint-Martin, Tami Rashal, Sharon Friedlander, Robert Carlson, Michael Kauffman, Sharon Shacham, Martin Gutierrez	2017	112
6	A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma Blood ·Darrell White, Nizar J. Bahlis, Christopher P. Venner, Gary J. Schiller, Cristina Gasparetto, Heather J. Sutherland, Michaël Sébag, Suzanne Lentzsch, Rami Kotb, William Bensinger, Brea Lipe, Christine I. Chen, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Richard LeBlanc	2017	4
7	Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM) Blood ·Nizar J. Bahlis, Heather J. Sutherland, Darrell White, Michaël Sébag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, Cristina Gasparetto, Gary J. Schiller, Richard LeBlanc, William Bensinger, Brea Lipe, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Christine I. Chen	2017	0
8	A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs) Blood ·Cristina Gasparetto, Suzanne Lentzsch, Gary J. Schiller, William Bensinger, Nizar J. Bahlis, Heather J. Sutherland, Darrell White, Michaël Sébag, Rami Kotb, Christopher P. Venner, Richard LeBlanc, Christine I. Chen, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Brea Lipe	2017	2
9	Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure Blood ·Christine I. Chen, Heather J. Sutherland, Rami Kotb, Michaël Sébag, Darrell White, William Bensinger, Cristina Gasparetto, Richard LeBlanc, Christopher P. Venner, Suzanne Lentzsch, Gary J. Schiller, Brea Lipe, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Nizar J. Bahlis	2017	3
10	XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus Clinical Cancer Research ·Parvathi Ranganathan, Trinayan Kashyap, Xueyan Yu, Xiaomei Meng, 潤一佐々木, 白岩謙一, Bhavana Bhatnagar, Sharon Shacham, Michael Kauffman, Adrienne M. Dorrance, William Blum, Deepa Sampath, Yosef Landesman, Ramiro Garzon	2016	67
11	Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma Molecular Cancer Therapeutics ·Amro Aboukameel, Irfana Muqbil, William Senapedis, Erkan Baloglu, Yosef Landesman, Sharon Shacham, Michael Kauffman, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi	2016	74
12	Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor Molecular Cancer Therapeutics ·Shaun Rosebeck, Yoshiko Yoda, Malathi Kandarpa, Anoop Mayampurath, Samuel L. Volchenboum, Jagoda Jasielec, Dominik Dytfeld, J.W. Mahony, 玉英呉, Dilara McCauley, Sharon Shacham, Michael Kauffman, Andrzej Jakubowiak	2015	40
13	Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition Scientific Reports ·Asfar S. Azmi, Irfana Muqbil, Jack Wu, Amro Aboukameel, William Senapedis, Erkan Baloglu, Aliccia Bollig‐Fischer, Gregory Dyson, Michael Kauffman, Yosef Landesman, Sharon Shacham, Philip A. Philip, Ramzi M. Mohammad	2015	29
14	XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer Molecular Cancer Therapeutics ·Yan Cheng, Michael P. Holloway, Kevin T. Nguyen, Dilara McCauley, Yosef Landesman, Michael Kauffman, Sharon Shacham, Rachel A. Altura	2014	83
15	KCP-330-005/SIGN: A phase II, open-label study of efficacy and safety of the selective inhibitor of nuclear export (SINE) KPT-330 (SELINEXOR) in patients with advanced gynaecologic malignancies International Journal of Gynecological Cancer ·游愛諾, Bente Lund, Shugerman Mr., Hanne Havsteen, Tami Rashal, John S. McCartney, Michael Kauffman, Sharon Shacham, Mansoor Raza Mirza	2014	2
16	Specific Inhibition of the Nuclear Exporter Exportin-1 Attenuates Kidney Cancer Growth PLoS ONE ·Hiromi I. Wettersten, Yosef Landesman, Sharon Friedlander, Sharon Shacham, Michael Kauffman, Robert H. Weiss	2014	23
17	Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells PLoS ONE ·Jennifer Yang, Matthew A. Bill, Gregory Young, Krista La Perle, Yosef Landesman, Sharon Shacham, Michael Kauffman, William Senapedis, Trinayan Kashyap, Jean‐Richard Saint‐Martin, Kari Kendra, Gregory B. Lesinski	2014	44
18	CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma Molecular Cancer Therapeutics ·Valery Grigoriev, Hye Won Chung, Yosef Landesman, William Senapedis, Jean‐Richard Saint‐Martin, Hensin Tsao, Keith T. Flaherty, Sharon Shacham, Michael Kauffman, James C. Cusack	2013	57
19	Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects. Blood ·Ravi Vij, Lühua Wang, Robert Z. Orlowski, A. Keith Stewart, Sundar Jagannath, Sagar Lonial, Suzanne Trudel, Andrzej Jakubowiak, Andrew Belch, Melissa Alsina, Nizar J. Bahlis, Mai H. Le, Scott Cruickshank, Mark K. Bennett, Susan M. Molineaux, Michael Kauffman, David S. Siegel	2009	13
20	Cell Cycle Regulation of Thymidine Kinase: Residues Near the Carboxyl Terminus Are Essential for the Specific Degradation of the Enzyme at Mitosis Molecular and Cellular Biology ·Michael Kauffman, Thomas J. Kelly	1991	37

About Michael Kauffman

Michael Kauffman is a scholar working on Hematology, Molecular Biology, Oncology, Cancer Research and Genetics, having authored 190 papers that have together received 5.6k indexed citations. Recurring topics across this work include Nuclear Structure and Function (111 papers), Multiple Myeloma Research and Treatments (33 papers), Cancer-related Molecular Pathways (33 papers), Protein Degradation and Inhibitors (23 papers), Cancer, Lipids, and Metabolism (20 papers), RNA Research and Splicing (20 papers), Acute Myeloid Leukemia Research (17 papers) and Ubiquitin and proteasome pathways (15 papers). The work is most often cited by research in Hematology (1.7k citations), Oncology (1.8k citations), Molecular Biology (4.3k citations), Genetics (468 citations) and Cancer Research (412 citations). Michael Kauffman has collaborated with scholars based in United States, Canada and Denmark. Frequent co-authors include Julian Adams, Sharon Shacham, Thomas J. Kelly, Yosef Landesman, Dilara McCauley, Asfar S. Azmi, William Senapedis, Amro Aboukameel, David S. Siegel and Ramzi M. Mohammad. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Research, Oncotarget and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact